Screening of the Open Source Malaria Box Reveals an Early Lead Compound for the Treatment of Alveolar Echinococcosis
Open Access
- 11 March 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 10 (3) , e0004535
Abstract
The metacestode (larval) stage of the tapeworm Echinococcus multilocularis causes alveolar echinococcosis (AE), a very severe and in many cases incurable disease. To date, benzimidazoles such as albendazole and mebendazole are the only approved chemotherapeutical treatment options. Benzimidazoles inhibit metacestode proliferation, but do not act parasiticidal. Thus, benzimidazoles have to be taken a lifelong, can cause adverse side effects such as hepatotoxicity, and are ineffective in some patients. We here describe a newly developed screening cascade for the evaluation of the in vitro efficacy of new compounds that includes assessment of parasiticidal activity. The Malaria Box from Medicines for Malaria Venture (MMV), comprised of 400 commercially available chemicals that show in vitro activity against Plasmodium falciparum, was repurposed. Primary screening was carried out at 10 μM by employing the previously described PGI assay, and resulted in the identification of 24 compounds that caused physical damage in metacestodes. Seven out of these 24 drugs were also active at 1 μM. Dose-response assays revealed that only 2 compounds, namely MMV665807 and MMV665794, exhibited an EC50 value below 5 μM. Assessments using human foreskin fibroblasts and Reuber rat hepatoma cells showed that the salicylanilide MMV665807 was less toxic for these two mammalian cell lines than for metacestodes. The parasiticidal activity of MMV665807 was then confirmed using isolated germinal layer cell cultures as well as metacestode vesicles by employing viability assays, and its effect on metacestodes was morphologically evaluated by electron microscopy. However, both oral and intraperitoneal application of MMV665807 to mice experimentally infected with E. multilocularis metacestodes did not result in any reduction of the parasite load. The fox tapeworm Echinococcus multilocularis causes a deadly disease in humans that is characterized by cancer-like parasite growth in the liver of patients. Hence E. multilocularis is ideally removed by radical resection. However, as this is not always possible, patients are treated by chemotherapy to stop further parasite growth. To date, the drugs in use cannot kill the parasite E. multilocularis and they also induce side-effects, therefore new options for treatment are needed. We here screened a library of 400 compounds with proven activity against Plasmodium falciparum, the cause of malaria, for their effects against E. multilocularis in vitro. We developed and refined an in vitro screening cascade and developed an assay that can identify compounds with parasiticidal effects against E. multilocularis cells. We here show that MMV665807 acts parasiticidal as demonstrated by in vitro viability tests and by electron microscopy. In the mouse infection model the drug was not active, but work will focus on the evaluation of derivatives with improved bioavailability and pharmacokinetic properties to achieve parasiticidal activity not only in vitro, but also in vivo.Keywords
This publication has 43 references indexed in Scilit:
- The Italian registry of cystic echinococcosis (RIEC): the first prospective registry with a European futureEurosurveillance, 2015
- On the importance of targeting parasite stem cells in anti-echinococcosis drug developmentParasite, 2014
- Identification of Cryptosporidium parvum Active Chemical Series by Repurposing the Open Access Malaria BoxAntimicrobial Agents and Chemotherapy, 2014
- The Open Access Malaria Box: A Drug Discovery Catalyst for Neglected DiseasesPLOS ONE, 2013
- Structure–activity relationships of antitubercular salicylanilides consistent with disruption of the proton gradient via proton shuttlingBioorganic & Medicinal Chemistry, 2013
- Antimalarials in the treatment of schistosomiasis.2012
- In VitroandIn VivoEfficacies of Mefloquine-Based Treatment against Alveolar EchinococcosisAntimicrobial Agents and Chemotherapy, 2011
- Echinococcus multilocularis phosphoglucose isomerase (EmPGI): A glycolytic enzyme involved in metacestode growth and parasite–host cell interactionsInternational Journal for Parasitology, 2010
- Thousands of chemical starting points for antimalarial lead identificationNature, 2010
- Artemisinins for schistosomiasis and beyond.2007